NCT03145623View on ClinicalTrials.gov

Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease

CompletedOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Hepatitis CChronic Kidney Diseases

Interventions

DRUG

Elbasvir and Grazoprevir

Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program

Trial Locations (2)

14000

University Hospital, Caen

31059

University Hospital Toulouse, Toulouse

All Listed Sponsors

collaborator

MSD France

INDUSTRY

lead

University Hospital, Toulouse

OTHER

NCT03145623 - Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter